Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
48.13
-1.36 (-2.75%)
Streaming Delayed Price
Updated: 11:39 AM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Crispr Therapeutics Ag
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Neurocrine Leads 5 Stocks To Watch In Sickly Market
September 03, 2022
Neurocrine Biosciences leads five medical stocks showing resilience.
Via
Investor's Business Daily
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
August 31, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
5 Top Stocks Cathie Wood Is Selling This Week
August 26, 2022
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling.
Via
InvestorPlace
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
August 22, 2022
These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit.
Via
InvestorPlace
Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock
August 17, 2022
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile.
Via
Benzinga
Where CRISPR Therapeutics Stands With Analysts
August 02, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,900 Today
August 17, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 19.58% on an annualized basis producing an average annual return of 31.2%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
August 09, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
August 09, 2022
Via
Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
August 09, 2022
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.
Via
Benzinga
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
August 09, 2022
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to...
Via
Benzinga
Small Cap Biotechs Perk Up On Dealmaking
August 06, 2022
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.
Via
Talk Markets
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
August 05, 2022
Shares of Pfizer's rumored takeover target have rocketed for two days running.
Via
Investor's Business Daily
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead
August 05, 2022
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.
Via
Benzinga
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
August 03, 2022
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.
Via
InvestorPlace
Will a Recession Cause a Housing Crash in 2022?
July 27, 2022
For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals.
Via
InvestorPlace
7 Undervalued Biotech Stocks to Buy Before They Boom
July 25, 2022
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.
Via
InvestorPlace
Small Cap Biotech Stocks Are Trending Well
July 18, 2022
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.
Via
Talk Markets
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
July 15, 2022
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.
Via
Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
July 15, 2022
The group has several commonalities, including strong ratings and promising charts.
Via
Investor's Business Daily
6 Cathie Wood Stocks to Buy on the Dip
July 14, 2022
As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers.
Via
InvestorPlace
Fed To Hike Interest Rates 100 Basis Points? What To Expect From Stocks
July 14, 2022
The CPI report came in at 9.1% well above analyst expectations. Now there is a strong possibility of a 100 basis point rate hike at the next FOMC meeting.
Via
Talk Markets
5 Best Stocks to Buy if You Have $100 to Spend
July 10, 2022
My son became an investor this year, taking a job that pays more than his single, frugal lifestyle consumes. He asked me what stocks he might buy with
Via
InvestorPlace
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.
Via
InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
July 07, 2022
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.
Via
Investor's Business Daily
Jim Cramer Says This Company Isn't Making Money
June 24, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is hearing nothing but positives of late about Nokia Corp (NYSE: NOK) over the previous four weeks. "I think it’s right to buy," he added.
Via
Benzinga
Evercore ISI Group Downgrades CRISPR Therapeutics: Here's What You Need To Know
June 23, 2022
Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
June 23, 2022
Upgrades
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.